Organization
UCB Pharma
10 clinical trials
23 abstracts
Clinical trial
A Multi-center, Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of 400mg/Day Lacosamide in Subjects With Painful Distal Diabetic Neuropathy Using Two Different Titration SchemesStatus: Completed, Estimated PCD: 2007-06-29
Clinical trial
An Open-label follow-on Trial to Assess the Long-term Safety and Efficacy of Oral SPM 927 in Subjects With Diabetic NeuropathyStatus: Completed, Estimated PCD: 2004-12-01
Clinical trial
A Multi-Center, Open-Label, Long-Term, Follow-Up Study Of The Safety And Efficacy Of Levetiracetam (Ucb L059) In Children With EpilepsyStatus: Completed, Estimated PCD: 2006-01-25
Clinical trial
A Multicenter, Double-blind, Double-dummy, Randomized Trial to Investigate the Safety, Tolerability and Pharmacokinetics of Intravenous SPM 927 as Replacement for Oral SPM 927 in Subjects With Partial Seizures With or Without Secondary GeneralizationStatus: Completed, Estimated PCD: 2004-08-17
Clinical trial
A Multi-Centre, Randomized, Double-Blind, Placebo Controlled Pilot Trial to Assess the Efficacy, Safety, and Tolerability of SPM 927 in Subjects With Postherpetic Neuralgia (PHN).Status: Completed, Estimated PCD: 2002-12-01
Clinical trial
A Multicenter, Open-label Trial to Assess the Long-term Safety and Efficacy of Lacosamide in Subjects With Painful Diabetic NeuropathyStatus: Completed, Estimated PCD: 2007-10-31
Clinical trial
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Study to Evaluate the Efficacy and Safety of Brivaracetam Used as Adjunctive Treatment for 12 Weeks in Adolescent and Adult Patients (≥ 16 Years) With Genetically Ascertained Unverricht-Lundborg DiseaseStatus: Completed, Estimated PCD: 2008-01-01
Clinical trial
An Open Label, Exploratory, Dose-escalation, Multicenter Study Examining the Safety, Tolerability and Efficacy of Ucb 44212 (Seletracetam) Used at Doses of 10, 20, 40, and 80 mg b.i.d. (Total Daily Doses of 20 - 160 mg) Administration (Oral Capsules) in Adult Subjects (18 - 65 Years) With Refractory Epilepsy Suffering From Partial Onset Seizures Who Are Currently Receiving Levetiracetam (LEV) But Still Experiencing SeizuresStatus: Completed, Estimated PCD: 2006-05-12
Clinical trial
Open-label, Single-arm, Multicenter, Long-term Study to Evaluate Safety and Efficacy of Brivaracetam Used as Adjunctive Treatment in Pediatric Subjects With EpilepsyStatus: Completed, Estimated PCD: 2022-02-03
Clinical trial
A Multi-center, Open-label, follow-on Trial to Assess the Long-term Safety and Efficacy of Lacosamide in Subjects With Painful Distal Diabetic Neuropathy Including a Double-blind, Randomized Time Point Withdrawal Subtrial.Status: Completed, Estimated PCD: 2011-01-01
Abstract
A “REAL-WORLD” CHARACTERIZATION OF MODERATE-TO-SEVERE SYSTEMIC LUPUS ERYTHEMATOSUS Org: Biopharmaceutical Consultant, Adelphi Real World Ltd, UCB Pharma,
Abstract
AN EXPLORATORY ANALYSIS OF THE POTENTIAL DISCONNECT BETWEEN OBJECTIVE INFLAMMATORY RESPONSE AND CLINICAL RESPONSE FOLLOWING CERTOLIZUMAB PEGOL TREATMENT IN PATIENTS WITH ACTIVE AXIAL SPONDYLOARTHRITISOrg: UCB Pharma, University of Bielefeld, Klinikum Bielefeld Rosenhöhe, Department of Internal Medicine and Rheumatology, Bielefeld, Germany, Ghent University and VIB Center for Inflammation Research, University of Leeds,
Abstract
A PHASE II RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PROOF OF CONCEPT STUDY OF ORAL SELETALISIB IN PATIENTS WITH PRIMARY SJÖGREN’S SYNDROME (PSS)Org: UCB Pharma, Newcastle University, Strasbourg University Hospital, University of Palermo, Université Paris-Sud,
Abstract
ANNUAL DIAGNOSTIC PREVALENCE OF ANKYLOSING SPONDYLITIS (AS) IN THE UNITED STATES USING MEDICARE AND MARKETSCAN DATAOrg: UCB Pharma,
Abstract
AWARENESS ABOUT FAMILY PLANNING AND PREGNANCY EXPECTATION AMONG PATIENTS WITH CHRONIC INFLAMMATORY DISEASE OF THE SKIN OR JOINTSOrg: UCB Pharma,
Abstract
BIMEKIZUMAB DUAL INHIBITION OF IL-17A AND IL-17F PROVIDES EVIDENCE OF IL-17F CONTRIBUTION TO CHRONIC INFLAMMATION IN DISEASE-RELEVANT CELLS Org: UCB Pharma, Slough, Brussels, Belgium,
Abstract
BIMEKIZUMAB EFFICACY IN HIGH-IMPACT AREAS FOR PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS: POOLED RESULTS THROUGH TWO YEARS FROM THE BE SURE AND BE RADIANT PHASE 3 TRIALSOrg: Harvard Medical School, Brigham and Women’s Hospital, The Icahn School of Medicine at Mount Sinai, Nagoya City University Graduate School of Medical Sciences, Hospital Universitari Germans Trias i Pujol,
Abstract
BASELINE CHARACTERISTICS OF RHEUMATOID ARTHRITIS PATIENTS STARTING CERTOLIZUMAB PEGOL THERAPY AND GLUCOCORTICOID PRESCRIPTION IN THE ECLAIR STUDY IN 2012–2013 Org: UCB Pharma, Cemka-Eval,
Abstract
BIMEKIZUMAB REDUCED MRI INFLAMMATORY LESIONS IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: WEEK 52 RESULTS FROM THE BE MOBILE 1 AND BE MOBILE 2 PHASE 3 STUDIESOrg: UCB Pharma,
Abstract
Barriers to rheumatoid arthritis treatment optimisation: real-world data from the arthritispower registryOrg: UCB Pharma, Smyrna, GA, Global Healthy Living Foundation, Upper Nyack, Upper Nyack, NY, University of Alabama at Birmingham Department of Hematology, Birmingham, AL,
Abstract
BASELINE PARAMETERS IDENTIFIED IN EARLY, METHOTREXATE-NAÏVE RHEUMATOID ARTHRITIS PATIENTS WITH BETTER OUTCOMES WITH CERTOLIZUMAB PEGOL+METHOTREXATE COMPARED TO PLACEBO+METHOTREXATE: POST-HOC ANALYSES OF C-OPERA, A RANDOMIZED, CONTROLLED, PHASE 3 SOrg: Hokkaido University Graduate School of Medicine, Hokkaido, The University of Tokyo, Tokyo, Japan, Keio University School of Medicine, Tokyo Women's Medical University, Tokyo, Japan, Nagoya University, Nagoya,
Abstract
BIMEKIZUMAB SAFETY AND EFFICACY IN PATIENTS WITH PSORIATIC ARTHRITIS: 3-YEAR RESULTS FROM A PHASE 2b OPEN-LABEL EXTENSION STUDYOrg: UCB Pharma, Brigham and Women’s Hospital, Sorbonne Université, University of Rochester Medical School, University of Oxford,
Abstract
BIMEKIZUMAB IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: 24-WEEK EFFICACY & SAFETY FROM BE MOBILE 2, A PHASE 3, MULTICENTRE, RANDOMISED, PLACEBO-CONTROLLED STUDYOrg: Genomics England, Charité – Universitätsmedizin Berlin, Ghent University and VIB Centre for Inflammation Research, University of Toronto, Shanghai Changzheng Hospital,
Abstract
BIMEKIZUMAB LONG-TERM SAFETY AND EFFICACY IN PATIENTS WITH ANKYLOSING SPONDYLITIS: 3-YEAR RESULTS FROM A PHASE 2B STUDYOrg: UCB Pharma,
Abstract
BIMEKIZUMAB MAINTAINED EFFICACY RESPONSES THROUGH 52 WEEKS IN BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUG-NAÏVE PATIENTS WITH PSORIATIC ARTHRITIS WHO WERE RESPONDERS AT WEEK 16: RESULTS FROM BE OPTIMAL, A PHASE 3, ACTIVE-REFERENCE STUDYOrg: UCB Pharma, ASST Gaetano Pini-CTO, Dept of Rheumatology, Milan, Italy, University of Milano, European Institute of Oncology, Division of Early Drug Development, Centre for Therapeutic Innovation, University of Bath,
Abstract
BIMEKIZUMAB ACHIEVED SUSTAINED IMPROVEMENTS IN EFFICACY OUTCOMES IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS, REGARDLESS OF PRIOR TNF INHIBITOR TREATMENT: WEEK 52 POOLED RESULTS FROM TWO PHASE 3 STUDIESOrg: UCB Pharma, Ruhr-University Bochum, Herne, University of Leeds,
Abstract
BIMEKIZUMAB IN PATIENTS WITH ACTIVE NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: 24-WEEK EFFICACY & SAFETY FROM BE MOBILE 1, A PHASE 3, MULTICENTRE, RANDOMISED, PLACEBO‑CONTROLLED STUDYOrg: UCB Pharma,
Abstract
BIMEKIZUMAB EFFICACY AND SAFETY IN BIOLOGIC DMARD-NAÏVE PATIENTS WITH PSORIATIC ARTHRITIS WAS CONSISTENT WITH OR WITHOUT METHOTREXATE: 52-WEEK RESULTS FROM THE PHASE 3 ACTIVE‑REFERENCE STUDY BE OPTIMALOrg: UCB Pharma, Fraunhofer Institute for Translational Medicine & Pharmacology ITMP,
Abstract
BIMEKIZUMAB IN BDMARD-NAIVE PATIENTS WITH PSORIATIC ARTHRITIS: 24-WEEK EFFICACY & SAFETY FROM BE OPTIMAL, A PHASE 3, MULTICENTRE, RANDOMISED, PLACEBO-CONTROLLED, ACTIVE REFERENCE STUDYOrg: UCB Pharma, Brigham and Women's Hospital/Massachusetts General Hospital, University of Glasgow, University of Oxford, Oxford University Hospitals NHS Trust,
Abstract
BIMEKIZUMAB SHOWS SUSTAINED LONG-TERM IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES AND QUALITY OF LIFE IN ANKYLOSING SPONDYLITIS: 3-YEAR RESULTS FROM A PHASE 2B STUDYOrg: Ruhr-University Bochum, Herne, Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Rheumatology, Bochum, Herne, Netherlands, Hôpital Cochin, Norfolk and Norwich University Hospital NHS Trust, The Royal National Hospital for Rheumatic Diseases,
Abstract
BETTER CLINICAL RESPONSES SEEN EARLY WITH THE LOADING DOSE OF CERTOLIZUMAB PEGOL ARE MAINTAINED UNTIL ONE YEAR Org: Keio University School of Medicine, University of Tokyo, Tokyo Women's Medical University, Tokyo, Japan, Nagoya University, Nagoya, University of Occupational and Environmental Health, Kitakyushu, Japan,